Effect of Neoadjuvant Chemotherapy on the Proliferative Ability of Tumor Cells and CD4+,CD8+T Lymphocytes in Stage Ⅲ Middle and Low Rectal Cancer
Objective:To investigate the effects of neoadjuvant chemotherapy on the proliferation ability of tumor cells and CD4+,CD8+T lymphocytes in stage Ⅲ middle and low rectal cancer.Methods:A retrospective analysis was conducted on 80 patients with stage Ⅲ mid to low rectal cancer in the First People's Hospital of Nanyang City from January 2020 to February 2023.According to different treatment plans,the two groups were divided into control group and observation group,with 40 patients in each group.Among them,the control group received only surgical treatment,while the observation group received neoadjuvant therapy and surgical treatment,and neoadjuvant chemotherapy was completed 2 weeks before surgical treatment.The surgical effects of the two groups of patients were compared and analyzed,including the tumor cell proliferation index and T lymphocytes(CD4+,CD8+,CD4+/CD8+).Results:There was no statistically significant difference in the surgical resection rate between the two groups of patients(x2=0.213,P＞0.05).The observation group had a higher anal preservation rate and a higher postoperative pathological complete response rate than the control group,with statistically significant difference(x2=5.000,4.943;P＜0.05).After treatment,the tumor cell proliferation index and CD8+T cells of the observation group were lower than those of the control group,and the CD4+T cells and CD4+/CD8+ratio were higher than those of the control group,with statistically significant difference(t=5.029,13.717,10.256;P＜0.05).Conclusion:The application of neoadjuvant chemotherapy in the treatment of stageⅢ middle and low rectal cancer patients has significant surgical effect,which can effectively inhibit the proliferation of tumor cells,improve the patient's immune function,and thus improve the ther prognosis.
万方数据
